Activation of the protective arm of renin-angiotensin system enhances mitochondrial turnover improving respiration and decreasing integrated stress response in a human Complex III deficiency model
Preprint
Abstract
Primary mitochondrial diseases are clinically and genetically heterogeneous disorders, commonly caused by defects in the oxidative phosphorylation system. This heterogeneity presents major challenges for therapeutic development; however, a shared hallmark across these diseases is the accumulation of dysfunctional mitochondria. Enhancing mitochondrial turnover, by activating the selective degradation of dysfunctional mitochondria via mitophagy, concurrently with the activation of mitochondrial biogenesis, could represent a shared therapeutic strategy for mitochondrial diseases. Here, we describe a novel mitophagy inducer, CAP-1902. CAP-1902 is a new agonist of the MAS G-Protein Coupled Receptor (MasR). In fibroblasts from patients carrying a BCS1L mutation that impairs complex III (CIII) assembly, CAP-1902 increased mitochondrial turnover by promoting both mitophagy and biogenesis. Specifically, MasR activation triggered the AMPK/ULK1/FUNDC1 mitophagy pathway. Knockdown of FUNDC1 blocked mitophagy but not AMPK activation, confirming pathway specificity. Additionally, a decrease in the occurrence of depolarized mitochondria with treatment indicated the selective targeting of accumulated damaged mitochondria in the disease context. MasR activation by CAP-1902 also stimulated the nuclear translocation of PGC-1α, promoting increased expression of transcripts associated with mitochondrial biogenesis, respiratory chain components, and mitochondrial translation. Remarkably, CAP-1902 was ultimately able to restore key defects in CIII-deficient fibroblasts by rescuing bioenergetics and correcting both the aberrant lysosomal distribution and the elevated integrated stress response markers, which is consistent with a shift toward a healthier mitochondrial population. In summary, we describe the first potential GPCR-mediated treatment of mitochondrial diseases and demonstrate that MasR activation by CAP-1902 induces mitochondrial turnover and improves mitochondrial function.Keywords
This publication has 66 references indexed in Scilit:
- BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b TrialJournal of Cachexia, Sarcopenia and Muscle, 2025
- COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2021
- Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and HumansMolecular Neurobiology, 2017
- The Use of DQ-BSA to Monitor the Turnover of Autophagy-Associated Cargo2017
- Structural insights into the recognition of phosphorylated FUNDC1 by LC3B in mitophagyProtein & Cell, 2016
- Critical role of AMP-activated protein kinase in the balance between mitophagy and mitochondrial biogenesis in MELAS diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- ULK1 translocates to mitochondria and phosphorylates FUNDC1 to regulate mitophagyEMBO Reports, 2014
- Analysis and Interpretation of Microplate-Based Oxygen Consumption and pH Data2014
- Effects of aging on food-entrained circadian rhythms in the ratNeurobiology of Aging, 1990
- A functional dichotomy in CD4+ T lymphocytesImmunology Today, 1988